GSE229973 cisplatin 4 v 5 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE229973_cisplatin_4_v_5_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE229973_cisplatin_4_v_5_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE229973_cisplatin_4_v_5_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE229973_cisplatin_4_v_5_human_up.

Results found

Linked to

 

Label

Description

 

Gene

zinc finger protein 839 pseudogene

Gene

small nucleolar RNA host gene 17

Gene

CENPB DNA-binding domains containing 2, pseudogene

Gene

HLA complex group 18

Gene

H3 clustered histone 6

Gene

Myb/SANT DNA binding domain containing 7

Gene

cytokine receptor like factor 2

Gene

ZNF496 divergent transcript

Gene

long intergenic non-protein coding RNA 857

Gene

FOXD2 adjacent opposite strand RNA 1

  • Gene

    zinc finger protein 839 pseudogene


  • Gene

    small nucleolar RNA host gene 17


  • Gene

    CENPB DNA-binding domains containing 2, pseudogene


  • Gene

    HLA complex group 18


  • Gene

    H3 clustered histone 6


  • Gene

    Myb/SANT DNA binding domain containing 7


  • Gene

    cytokine receptor like factor 2


  • Gene

    ZNF496 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 857


  • Gene

    FOXD2 adjacent opposite strand RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.